Swiss exporters are relocating parts of their operations overseas following adjustments to U.S. tariffs, with many firms planning to move production or increase investment abroad, according to a survey by business association economiesuisse. Despite a recent agreement reducing U.S. duties from 39 percent to 15 percent, nearly a third of surveyed companies said they intend to expand investment outside Switzerland and shift production overseas.
Some firms are exploring relocation beyond both the European Union and the United States, while others are assessing new markets, adjusting prices, or pausing U.S.-bound exports. Economiesuisse’s chief economist, Rudolf Minsch, said Switzerland remains attractive for business, though some companies are seeking alternative production bases to manage costs.
Ethiopia maintains established diplomatic and economic ties with Switzerland, dating back to 1952, supported by agreements including a double taxation treaty. Bilateral trade reached approximately CHF 77 million in 2024, with Ethiopia exporting mainly agricultural products, including coffee, and importing machinery, pharmaceuticals, and technical equipment.
Experts say the Swiss shift could influence global investment flows. Firms seeking lower-cost production bases may increasingly consider emerging markets such as Ethiopia. A reduction in outbound Swiss investment could affect capital inflows and technology transfer, while the country’s ability to attract relocated production will depend on regulatory stability, infrastructure, and investment policies.
Pharmaceuticals, Switzerland’s largest export sector, are central to these shifts. UBS projects that relocating all U.S.-bound Swiss pharmaceutical production could reduce Swiss economic growth over five years from 10 percent to 7.7 percent, illustrating the strategic considerations companies weigh when reorganising global production.
